Literature DB >> 15713955

Failing survival advantage in crucial trial, future of Iressa is in jeopardy.

Renee Twombly.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15713955     DOI： 10.1093/jnci/97.4.249

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

1.  Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index.

Authors:  Xiang Li; Varsha Rao; Jin Jin; Bin Guan; Kenna L Anderes; Charles J Bieberich
Journal:  J Proteome Res       Date:  2012-06-18       Impact factor: 4.466

2.  Integrating molecular diagnostics into anticancer drug discovery.

Authors:  István Peták; Richárd Schwab; László Orfi; László Kopper; György Kéri
Journal:  Nat Rev Drug Discov       Date:  2010-06-07       Impact factor: 84.694

3.  Bad patients meet good drugs.

Authors:  Juan Carlos Lacal
Journal:  Clin Transl Oncol       Date:  2006-04       Impact factor: 3.405

4.  Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.

Authors:  Mary E Irwin; Kelly L Mueller; Natacha Bohin; Yubin Ge; Julie L Boerner
Journal:  J Cell Physiol       Date:  2011-09       Impact factor: 6.384

5.  Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Authors:  Kelly L Mueller; Lauren A Hunter; Stephen P Ethier; Julie L Boerner
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.

Authors:  A Sutani; Y Nagai; K Udagawa; Y Uchida; N Koyama; Y Murayama; T Tanaka; H Miyazawa; M Nagata; M Kanazawa; K Hagiwara; K Kobayashi
Journal:  Br J Cancer       Date:  2006-11-14       Impact factor: 7.640

7.  Bioinformatics Study of Sea Cucumber Peptides as Antibreast Cancer Through Inhibiting the Activity of Overexpressed Protein (EGFR, PI3K, AKT1, and CDK4).

Authors:  Teresa Liliana Wargasetia; Hana Ratnawati; Nashi Widodo; Muhammad Hermawan Widyananda
Journal:  Cancer Inform       Date:  2021-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.